It is a Phase 2/3, Open-Label Study to confirm the dose of elvitegravir/cobicistat/emtricitabin e/tenofoviralafenamide (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected, antiretroviral (ARV) treatment naive adolescents and evaluate the…